Reviews/Heart Failure Management/HeartMate 3 superior to axial-flow left ventricular assist devices
Lvad · HFM-LVAD-01 · v2
A single large randomized trial comparing the HeartMate 3 pump with the older HeartMate II found the newer pump much less likely to need replacement for clotting and associated with fewer strokes [15]. Five-year follow-up and secondary analyses of the same trial pointed the same way, with stroke, bleeding and pump thrombosis all less frequent on the HeartMate 3 [1][3][4]. The panel accepted that the direction of benefit is clear and durable, and that the trial itself described its advantage as driven by blood-compatibility outcomes [5]. It stopped short of the top tier because essentially all the evidence comes from one industry-funded trial program against a single older device, and because the specific 'disabling stroke' part of the claim is not shown as cleanly as the clotting part. Infection rates were not improved by the device, which limits how broadly the superiority can be read [5].
The pivotal trial [15] reported pump replacement in 2.3% vs 11.3% of patients (relative risk 0.21) and superiority on the composite of survival free of disabling stroke or reoperation (relative risk 0.84, P<0.001). Five-year follow-up [1] found the composite 54.0% vs 29.7% (hazard ratio 0.55) and stated stroke, bleeding and pump thrombosis were less frequent with the centrifugal-flow pump. A prespecified secondary analysis [3] showed the HeartMate 3 superior in both bridge-to-transplant and destination-therapy groups (hazard ratios 0.62 and 0.61). A dedicated stroke analysis [4] found long-term stroke 3.3 times lower (odds ratio 0.23). The trial-level analysis [5] attributes the superiority to hemocompatibility-related outcomes while finding infection unchanged. The contested point: The division is over independence and specificity: every comparative datapoint comes from the Abbott-funded MOMENTUM 3 program against the HeartMate II alone [1][3][4][5][15], and the pivotal interim benefit was framed as 'pump thrombosis or nondisabling stroke' [15], so the disabling-stroke component the claim names is not isolated and the composite is heavily driven by pump replacement [15].
All 15 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Heart Failure Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Nearly all comparative evidence ([1][3][4][5][15]) comes from a single RCT program, MOMENTUM 3, sponsored by Abbott (the HM3 manufacturer); [2] adds only HM3-vs-HM3 data. Evidential independence is minimal.
The claim names 'disabling stroke' specifically, but the pivotal trial's described hemocompatibility benefit was framed as 'pump thrombosis or nondisabling stroke'; disabling-stroke superiority is not separately demonstrated in the included primary data and the composite superiority is largely driven by reoperation/pump replacement.
Where it remains uncertain. All comparative evidence is MOMENTUM 3 against the HeartMate II alone [1][3][4][5][15], the disabling-stroke component specifically is not separately demonstrated [15], and infection was not improved by device [5].
Aleatory
The dedicated stroke analysis rests on 65 strokes in 361 patients [4], so the long-term stroke estimate (odds ratio 0.23, 95% CI 0.08-0.63) carries wide sampling uncertainty
Epistemic
All comparative evidence is MOMENTUM 3, funded by the manufacturer [1][3][4][5][15], so no independent replication exists in the corpus
Inferential
The pivotal benefit was framed as 'pump thrombosis or nondisabling stroke' [15], so inferring separate disabling-stroke superiority goes beyond what the primary data isolate
The load-bearing papers from a corpus of 15, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Durable 5-year confirmation of lower HRAEs including pump thrombosis and stroke
“Serious adverse events of stroke, bleeding, and pump thrombosis were less frequent in the centrifugal-flow pump group.”
Panel auditInternal validity: high · scope of inference: Advanced heart failure patients implanted with HM3 or HMII who were still on LVAD support at 2 years, over 5-year follow-up in 69 US centres.Key limitations: observational extension of RCT · conditioned on 2-year survival (survivor selection) · industry (Abbott) trial · AE comparison stated qualitatively without numbers in abstract
Shows superiority is consistent across patient strategy subgroups
“HM3 use was superior to HMII use in patients in the BTT/BTC group (76.8% vs 67.3% for survival free of disabling stroke and reoperation; hazard ratio, 0.62 [95% CI, 0.40-0.94]; log-rank P = .02)”
Panel auditInternal validity: high · scope of inference: Advanced heart failure patients stratified by transplant-intent (BTT/BTC vs DT) at 2 years.Key limitations: secondary subgroup analysis · component AE reductions reported as not significantly different between subgroups · industry trial
Isolates and quantifies the stroke-reduction component of the claim
“stroke incidence in the long-term period (181-730 days after left ventricular assist device) was 3.3 times lower for the HM3 group (HM3: 0.04 versus HMII: 0.13 events per patient-year; odds ratio, 0.23; 95% CI, 0.08-0.63; P=0.01)”
Panel auditInternal validity: high · scope of inference: Advanced heart failure LVAD recipients, stroke events over 2 years of support.Key limitations: benefit confined to long-term (>6 month) period · early-period stroke rates equivalent · industry trial
The study's comparison is between two HeartMate 3 populations, so it reports no head-to-head contrast of the centrifugal-flow device against an axial-flow device for hemocompatibility events.
Panel auditInternal validity: medium · scope of inference: Real-world/expanded-access HeartMate 3 recipients compared with the HM3 pivotal cohort at 2 years.Key limitations: no axial-flow comparator arm · HM3-vs-HM3 cohort comparison only · single device analysis
4 of 15 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Strong, concordant, durable RCT evidence is held below Established by dependence on a single industry-funded trial program against one axial device and by weaker isolation of the disabling-stroke-specific component.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent replication outside the manufacturer's program. Every comparative datapoint is MOMENTUM 3, funded by the HeartMate 3 maker [1][3][4][5][15], so the effect has no independent confirmation in the corpus The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An investigator-initiated or registry-based comparative study of the HeartMate 3 against axial-flow devices with no manufacturer sponsorship
Open question: Is the HeartMate 3 superior to axial-flow devices other than the HeartMate II? Why it is still open: The only axial comparator in the corpus is the HeartMate II [3][15]
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19